Equities

Amneal Pharmaceuticals Inc

Amneal Pharmaceuticals Inc

Actions
  • Price (USD)8.73
  • Today's Change0.12 / 1.39%
  • Shares traded1.72m
  • 1 Year change+115.02%
  • Beta1.1411
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments9226248
Total Receivables, Net646797728
Total Inventory581531489
Prepaid expenses504745
Other current assets, total9.771110
Total current assets1,3781,4121,520
Property, plant & equipment, net550589639
Goodwill, net599599593
Intangibles, net8901,0961,167
Long term investments------
Note receivable - long term------
Other long term assets489713
Total assets3,4733,7993,940
LIABILITIES
Accounts payable144166131
Accrued expenses403383404
Notes payable/short-term debt179600
Current portion long-term debt/capital leases373334
Other current liabilities, total8411050
Total current liabilities847753677
Total long term debt2,4862,6922,778
Total debt2,7022,7862,812
Deferred income tax------
Minority interest42(89)24
Other liabilities, total79145100
Total liabilities3,4533,5013,579
SHAREHOLDERS EQUITY
Common stock3.073.043.01
Additional paid-in capital539692658
Retained earnings (accumulated deficit)(490)(406)(276)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(32)9.94(25)
Total equity20298360
Total liabilities & shareholders' equity3,4733,7993,940
Total common shares outstanding459304302
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.